Oppenheimer analyst Hartaj Singh maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $400 to $575.
Oppenheimer Maintains Outperform on United Therapeutics, Raises Price Target to $575
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.